Dss, Inc 10-Q for FY2026 Q2

Dss, Inc. (DSS)

10-Q 2026-08-14 For: 2026-06-30

Added on August 14, 2026

About this 10-Q

Dss, Inc filed this 10-Q on August 14, 2026, covering the quarter ended June 30, 2026 (FY2026 Q2).

Headline figures

Quarter ended June 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue: $3.6M; down 31.8% from $5.29M a year earlier
Net loss: $4.79M; compared with a net loss of $2.15M a year earlier

Search and read filings like this one from Claude or ChatGPT with the SEC filings MCP server →

Large accelerated filer ☐	Accelerated filer ☐	Non-accelerated filer ☒	Smaller reporting company ☒

Emerging growth company ☐

Title of each class		Ticker symbol(s)		Name of each exchange on which registered
Common Stock, $0.02 par value per share		DSS		The NYSE American LLC

PART I	FINANCIAL INFORMATION
Item 1
	Condensed Consolidated Balance Sheets as of June 30, 2026 (unaudited) and December 31, 2025 (unaudited)	3
	Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2026 and 2025 (unaudited)	4
	Condensed Consolidated Statement of Changes in Stockholders’ Equity for the three and six months ended June 30, 2026 and 2025 (unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2026 and 2025 (unaudited)	6
	Notes to Interim Condensed Consolidated Financial Statements (unaudited)	7
Item 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	29
Item 4	Controls and Procedures	34

PART II	OTHER INFORMATION	35
Item 1	Legal Proceedings	35
Item 1A	Risk Factors	35
Item 2	Unregistered Sales of Equity Securities and Use of Proceeds	35
Item 3	Defaults upon Senior Securities	35
Item 4	Mine Safety Disclosures	35
Item 5	Other Information	35
Item 6	Exhibits	35

	As of June 30, 2026			As of December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents	$	4,068,000		$	6,214,000
Restricted cash		-			100,000
Accounts receivable, net		1,286,000			2,254,000
Inventory		1,978,000			1,998,000
Investments in trading securities		1,090,000			2,694,000
Current portion of notes receivable, net		248,000			198,000
Current portion of notes receivable - related party		231,000			238,000
Current portion of notes receivable		231,000			238,000
Prepaid expenses and other current assets		467,000			649,000
Total current assets		9,368,000			14,345,000

Property, plant and equipment, net		4,610,000			4,819,000
Investment in real estate, net		16,357,000			16,637,000
Investment, cost method		500,000			500,000
Investment, equity method		11,994,000			113,000
Investment in equity securities		1,719,000			6,517,000
Other assets		65,000			71,000
Right-of-use assets		5,510,000			5,825,000
Goodwill		1,769,000			1,769,000
Other intangible assets, net		16,459,000			17,034,000
Total assets	$	68,351,000		$	67,630,000

LIABILITIES AND STOCKHOLDERS’ EQUITY

Current liabilities:
Accounts payable	$	3,187,000		$	2,597,000
Accrued expenses and deferred revenue		2,060,000			1,725,000
Other current liabilities		3,185,000			4,367,000
Accrued interest on long-term debt		8,332,000			7,162,000
Current portion of lease liability		603,000			611,000
Current portion of long-term debt, net		30,321,000			30,343,000
Convertible note payable - related party, net		1,376,000			503,000
Current portion of long-term debt - related party, net		178,000			188,000
Current portion of long-term debt		178,000			188,000
Total current liabilities		49,242,000			47,496,000

Long-term debt, net		5,272,000			5,727,000
Long term lease liability		5,387,000			5,692,000
Total liabilities		59,901,000			58,915,000

Commitments and contingencies (Note 13)		-

Stockholders’ equity (deficit)
Preferred stock, $.02 par value; 47,000 shares authorized, zero shares issued and outstanding on June 30, 2026 (zero on December 31, 2025)		-			-
Common stock, $.02 par value; 200,000,000 shares authorized, 10,042,518 shares issued and outstanding on June 30, 2026 (9,092,518 on December 31, 2025)		200,000			182,000
Additional paid-in capital		336,808,000			325,987,000
Accumulated deficit		(337,390,000	)		(327,001,000	)
Total stockholders’ equity of the Company		(382,000	)		(832,000	)
Non-controlling interest in subsidiaries		8,832,000			9,547,000
Total stockholders’ equity		8,450,000			8,715,000

Total liabilities and stockholders’ equity	$	68,351,000		$	67,630,000

	2026			2025			2026			2025
	For the Three Months Ended June 30,						For the Six Months Ended June 30,
	2026			2025			2026			2025
Revenue:
Printed products	$	3,258,000		$	4,272,000		$	7,405,000		$	8,255,000
Rental		245,000			715,000			392,000			1,429,000
Commercial lending		6,000			9,000			12,000			29,000
Commission		92,000			282,000			115,000			503,000
Biotechnology		3,000			7,000			10,000			21,000
Total revenue		3,604,000			5,285,000			7,934,000			10,237,000

Costs and expenses:
Cost of revenue		4,519,000			5,489,000			10,052,000			10,665,000
Selling, general and administrative (including stock-based compensation)		2,871,000			3,221,000			7,156,000			6,723,000
Total costs and expenses		7,390,000			8,710,000			17,208,000			17,388,000
Operating loss		(3,786,000	)		(3,425,000	)		(9,274,000	)		(7,151,000	)

Other income (expense):
Interest income		2,000			13,000			3,000			17,000
Interest income on note receivable, related party		6,000			12,000			12,000			16,000
Dividend income		5,000			-			16,000			-
Other income (expense)		21,000			4,000			7,000			10,000
Interest expense		(89,000	)		(123,000	)		(128,000	)		(156,000	)
Loss on equity method investment		(364,000	)		(2,000	)		(367,000	)		(5,000	)
(Loss) gain on investments		(830,000	)		1,557,000			(1,531,000	)		627,000
Impairment of intangible assets		-			(600,000	)		-			(600,000	)
Loss on sale of real estate		-			(43,000	)		-			(727,000	)
Loss from continuing operations before income taxes		(5,035,000	)		(2,607,000	)		(11,262,000	)		(7,969,000	)

Income tax benefit		-			-			-			67,000
Net loss	$	(5,035,000	)	$	(2,607,000	)	$	(11,262,000	)	$	(7,902,000	)

Loss from operations attributed to noncontrolling interest		246,000			455,000			873,000			973,000

Net loss attributable to DSS common stockholders	$	(4,789,000	)	$	(2,152,000	)	$	(10,389,000	)	$	(6,929,000	)

Loss per common share attributable to common stock holders
Basic	$	(0.48	)	$	(0.24	)	$	(1.06	)	$	(0.78	)
Diluted	$	(0.48	)	$	(0.24	)	$	(1.06	)	$	(0.78	)

Shares used in computing loss per common share:
Basic		10,042,518			9,092,518			9,847,214			8,889,221
Diluted		10,042,518			9,092,518			9,847,214			8,889,221

	Shares		Amount		Shares		Amount		in Capital		Deficit			Equity			Subsidiary			Total
	Common Stock				Preferred Stock				Additional Paid-		Accumulated			Total DSS			Non- controlling Interest in
	Shares		Amount		Shares		Amount		in Capital		Deficit			Equity			Subsidiary			Total

Balance, December 31, 2024		8,092,518	$	161,000		-	$	-	$	323,150,000	$	(303,072,000	)	$	20,239,000		$	12,477,000		$	32,716,000
															-
Stock-based payments for professional services		-		-		-		-		190,000		-			190,000			-			190,000
Stock-based payments		-		-		-		-		4,000		-			4,000			-			4,000
Issuance of common stock, net of expenses - Impact BioMedical, Inc.		-		1,000		-		-		1,294,000		-			1,295,000			205,000			1,500,000
Issuance of common stock for bonus		1,000,000		20,000		-		-		850,000		-			870,000			-			870,000
Net loss		-		-		-		-		-		(6,929,000	)		(6,929,000	)		(973,000	)		(7,902,000	)
Balance, June 30, 2025		9,092,518	$	182,000		-	$	-	$	325,488,000	$	(310,001,000	)	$	15,669,000		$	11,709,000		$	27,378,000

Balance, December 31, 2025		9,092,518		182,000		-		-		325,987,000		(327,001,000	)		(832,000	)		9,547,000			8,715,000
Balance		9,092,518		182,000		-		-		325,987,000		(327,001,000	)		(832,000	)		9,547,000			8,715,000

Issuance of common stock, net of expenses		950,000		18,000		-		-		685,000		-			703,000			-			703,000
Fair value adjustment related to convertible bond received from related party		-		-		-		-		6,198,000		-			6,198,000			-			6,198,000
Issuance of warrants in connection with convertible promissory note		-		-		-		-		2,656,000		-			2,656,000			-			2,656,000
Stock-based payments - Impact BioMedical, Inc.		-		-		-		-		1,282,000		-			1,282,000			158,000			1,440,000
Net loss		-		-		-		-		-		(10,389,000	)		(10,389,000	)		(873,000	)		(11,262,000	)
Balance, June 30, 2026		10,042,518	$	200,000		-	$	-	$	336,808,000	$	(337,390,000	)	$	(382,000	)	$	8,832,000		$	8,450,000
Balance		10,042,518	$	200,000		-	$	-	$	336,808,000	$	(337,390,000	)	$	(382,000	)	$	8,832,000		$	8,450,000

	2026			2025
Cash flows from operating activities:
Net loss	$	(11,262,000	)	$	(7,902,000	)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization		1,278,000			1,058,000
Issuance of common stock for bonus		-			870,000
Stock-based payments for professional services rendered		-			190,000
Stock-based payments to employees and directors		1,440,000			4,000
Loss on equity method investment		367,000			5,000
Unrealized loss on investments		818,000			303,000
Change in ROU assets		315,000			330,000
(Loss) gain on allowance for obsolescence of inventory		2,000			(21,000	)
Provision for loan loss recoveries		-			235,000
Impairment of intangible asset		-			600,000
Amortization of debt discount		32,000			-
Loss on sale of real estate		-			250,000
Decrease (increase) in assets:
Accounts receivable		968,000			380,000
Inventory		18,000			(80,000	)
Assets held for sale		-			(38,000	)
Prepaid expenses and other current assets		182,000			241,000
Investments in trading securities		1,984,000			(884,000	)
Other assets		6,000			(802,000	)
Increase (decrease) in liabilities:
Accounts payable		590,000			(287,000	)
Accrued expenses		334,000			(26,000	)
ROU liabilities		(313,000	)		(313,000	)
Accrued interest on notes payable		1,208,000			1,884,000
Other liabilities		48,000			3,549,000
Net cash (used) provided by operating activities		(1,985,000	)		(454,000	)

Cash flows from investing activities:
Purchase of property, plant and equipment		(214,000	)		(144,000	)
Purchase of convertible bond - related party		(2,450,000	)		-
Sale of real estate		-			9,500,000
Sale of investment, related party		-			1,500,000
Issuance of new notes receivable, net origination fees		(50,000	)
Payments received on notes receivable		7,000			163,000
Net cash (used) provided by investing activities		(2,707,000	)		11,019,000

Cash flows from financing activities:
Payments of long-term debt		(628,000	)		(9,443,000	)
Borrowings of long-term debt, net		73,000			109,000
Payment on margin loans		(1,152,000	)		(3,178,000	)
Borrowings of convertible note payable - related party		3,450,000			-
Issuances of common stock, net of issuance costs		703,000			-
Net cash provided (used) by financing activities		2,446,000			(12,512,000	)

Net decrease in cash		(2,246,000	)		(1,947,000	)
Cash, cash equivalents and restricted cash at beginning of period		6,314,000			11,431,000

Cash and cash equivalents at end of period	$	4,068,000		$	9,484,000

	June 30, 2026			December 31, 2025
Finished Goods	$	1,083,000		$	807,000
Work in Process		223,000			498,000
Raw Materials		727,000			746,000
Inventory gross	$	2,033,000		$	2,051,000
Less allowance for obsolescence		(55,000	)		(53,000	)
Inventory net	$	1,978,000		$	1,998,000

	June 30, 2026
	Cost		Unrealized Gain/(Loss)			Fair Value		Cash and Cash Equivalents		Marketable Securities
Cash	$	4,013,000	$	-		$	4,013,000	$	4,013,000	$	-
Restricted Cash		-		-			-		-		-
Level 1
Money Market Funds		55,000		-			55,000		55,000		-
Marketable Securities		16,511,000		(13,702,000	)		2,809,000		-		2,809,000
Total	$	20,579,000	$	(13,702,000	)	$	6,877,000	$	4,068,000	$	2,809,000

	December 31, 2025
	Adjusted Cost		Unrealized Gain/(Loss)			Fair Value		Cash and Cash Equivalents		Marketable Securities
Cash	$	4,981,000	$	-		$	4,981,000	$	4,981,000	$	-
Restricted Cash		100,000		-			100,000		100,000		-
Level 1
Money Market Funds		1,233,000		-			1,233,000		1,233,000		-
Marketable Securities		26,383,000		(17,172,000	)		9,211,000		-		9,211,000
Total	$	32,697,000	$	(17,172,000	)	$	15,525,000	$	6,314,000	$	9,211,000

Year	Debt		Convertible note payable - related party		Notes payable - related party		Total
2026	$	29,419,000	$	1,376,000	$	178,000	$	30,973,000
2027		938,000				-		938,000
2028		986,000				-		986,000
2029		504,000				-		504,000
2030		235,000		-		-		235,000
Thereafter		3,511,000				-		3,511,000
Total	$	35,593,000	$	1,376,000	$	178,000	$	37,147,000


2026	$	412,000
2027		808,000
2028		824,000
2029		840,000
2030		857,000
After		3,216,000
Total lease payments	$	6,957,000
Less imputed interest		(967,000	)
Present value of remaining lease payments	$	5,990,000

Current	$	603,000
Non-current	$	5,387,000

Weighted average remaining lease term (years)		8.2

Weighted average discount rate		3.8	%

	2026		2025

Cash paid for interest	$	107,000	$	1,963,000

Non-cash investing and financing activities:
Fair value adjustment related to convertible bond received from related party	$	6,198,000	$	-
Conversion of convertible bond investment – related party into equity method investment	$	8,647,000		-
Transfer of investment in equity securities to equity method investment upon obtaining significant influence	$	3,600,000
Issuance of warrants in connection with convertible promissory note from related party	$	2,656,000	$	-

Three Months Ended June 30, 2026	Product Packaging			Commercial Lending			Biotechnology			Securities			Corporate/ Other			Total
Revenue	$	3,274,000		$	6,000		$	3,000		$	321,000		$	-		$	3,604,000
Cost of Revenue		3,357,000			-			1,000			1,161,000			-			4,519,000
Gross profit (loss)		(83,000	)		6,000			2,000			(840,000	)		-			(915,000	)
Operating expense		873,000			94,000			699,000			331,000			874,000			2,871,000
Operating income (loss)		(956,000	)		(88,000	)		(697,000	)		(1,171,000	)		(874,000	)		(3,786,000	)
Other income (expense)		(28,000	)		37,000			2,000			(177,000	)		(1,083,000	)		(1,249,000	)
Net income (loss) from operations before taxes	$	(984,000	)	$	(51,000	)	$	(695,000	)	$	(1,384,000	)	$	(1,957,000	)	$	(5,035,000	)

Three Months Ended June 30, 2025	Product Packaging			Commercial Lending			Biotechnology			Securities			Corporate/ Other			Total
Revenue	$	4,288,000		$	9,000		$	7,000		$	981,000		$	-		$	5,285,000
Cost of revenue		4,094,000			234,000			3,000			1,165,000			(7,000	)		5,489,000
Gross profit (loss)		194,000			(225,000	)		4,000			(184,000	)		7,000			(204,000	)
Operating expense		754,000			75,000			1,195,000			737,000			460,000			3,221,000
Operating income (loss)		(560,000	)		(300,000	)		(1,191,000	)		(921,000	)		(453,000	)		(3,425,000	)
Other income (expense)		(37,000	)		(170,000	)		3,000			107,000			915,000			818,000
Net income (loss) from operations before taxes	$	(597,000	)	$	(470,000	)	$	(1,188,000	)	$	(814,000	)	$	462,000		$	(2,607,000	)

Six Months Ended June 30, 2026	Product Packaging			Commercial Lending			Biotechnology			Securities			Corporate/ Other			Total
Revenue	$	7,438,000		$	11,000		$	10,000		$	475,000		$	-		$	7,934,000
Cost of Revenue		7,796,000			-			1,000			2,255,000			-			10,052,000
Gross profit (loss)		(358,000	)		11,000			9,000			(1,780,000	)		-			(2,118,000	)
Operating expense		1,772,000			170,000			3,004,000			649,000			1,561,000			7,156,000
Operating income (loss)		(2,130,000	)		(159,000	)		(2,995,000	)		(2,429,000	)		(1,561,000	)		(9,274,000	)
Other income (expense)		(59,000	)		45,000			7,000			170,000			(2,151,000	)		(1,988,000	)
Net income (loss) from operations before taxes	$	(2,189,000	)	$	(114,000	)	$	(2,988,000	)	$	(2,259,000	)	$	(3,712,000	)	$	(11,262,000	)

Six Months Ended June 30, 2025	Product Packaging			Commercial Lending			Biotechnology			Securities			Corporate/ Other			Total
Revenue	$	8,286,000		$	30,000		$	21,000		$	1,900,000		$	-		$	10,237,000
Cost of revenue		7,895,000			212,000			4,000			2,561,000			(7,000	)		10,665,000
Gross profit (loss)		391,000			(182,000	)		17,000			(661,000	)		7,000			(428,000	)
Operating expense		1,464,000			140,000			2,261,000			899,000			1,959,000			6,723,000
Operating income (loss)		(1,073,000	)		(322,000	)		(2,244,000	)		(1,560,000	)		(1,952,000	)		(7,151,000	)
Other income (expense)		(75,000	)		(416,000	)		46,000			(970,000	)		597,000			(818,000	)
Net income (loss) from operations before taxes	$	(1,148,000	)	$	(738,000	)	$	(2,198,000	)	$	(2,530,000	)	$	(1,355,000	)	$	(7,969,000	)

Three months ended June 30, 2026
Packaging Printing and Fabrication	$	3,029,000
Commercial and Security Printing		233,000
Real Property Rental Income		12,000
Total Printed Products Revenue	$	3,274,000

Three months ended June 30, 2025
Packaging Printing and Fabrication	$	4,157,000
Commercial and Security Printing		122,000
Real Property Rental Income		9,000
Total Printed Products Revenue	$	4,288,000

Six months ended June 30, 2026
Packaging Printing and Fabrication	$	7,071,000
Commercial and Security Printing		344,000
Real Property Rental Income		23,000
Total Printed Products Revenue	$	7,438,000

Six months ended June 30, 2025
Packaging Printing and Fabrication	$	8,018,000
Commercial and Security Printing		257,000
Real Property Rental Income		11,000
Total Printed Products Revenue	$	8,286,000

Three months ended June 30, 2026
Net investment income	$	6,000
Total Commercial Lending Revenue	$	6,000

Three months ended June 30, 2026
Retail internet sales	$	3,000
Total Biotechnology Revenue	$	3,000

Three months ended June 30, 2026
Rental income	$	229,000
Commission income		92,000
Total Securities Revenue	$	321,000

Six months ended June 30, 2026
Rental income	$	360,000
Commission income		115,000
Total Securities Revenue	$	475,000

Six months ended June 30, 2025
Rental income	$	1,397,000
Commission income		503,000
Total Securities Revenue	$	1,900,000

	Three months ended June 30, 2026		Three months ended June 30, 2025		% Change			Six months ended June 30, 2026		Six months ended June 30, 2025		% Change
Product Packaging	$	3,258,000	$	4,281,000		-24	%	$	7,438,000	$	8,286,000		-10	%
Securities		337,000		981,000		-66	%		475,000		1,900,000		-75	%
Commercial Lending		6,000		16,000		-63	%		11,000		30,000		-63	%
Biotechnology		3,000		7,000		-57	%		10,000		21,000		-52	%

	$	3,604,000	$	5,285,000		-32	%	$	7,934,000	$	10,237,000		-22	%

	Three months ended June 30, 2026		Three months ended June 30, 2025			% Change			Six months ended June 30, 2026		Six months ended June 30,2025		% Change

Cost of revenue
Printed products	$	3,357,000	$	4,094,000			-18	%	$	7,796,000	$	7,895,000		-1	%
Securities		1,161,000		1,165,000			0	%		2,255,000		2,561,000		-12	%
Biotechnology		1,000		3,000			-67	%		1,000		4,000		-75	%
Commercial lending		-		234,000			-100	%		-		212,000		-100	%
Other		-		(7,000	)		-100	%		-		3,000		-100	%
Sales, general and administrative compensation		1,043,000		1,122,000			-7	%		2,042,000		3,167,000		-36	%
Professional fees		625,000		492,000			27	%		1,222,000		1,131,000		8	%
Stock-based compensation		-		2,000			-100	%		1,440,000		3,000		47900	%
Sales and marketing		357,000		423,000			-16	%		733,000		824,000		-11	%
Rent and utilities		129,000		133,000			-3	%		261,000		259,000		1	%
Research and development		76,000		75,000			1	%		123,000		178,000		-31	%
Other operating expenses		641,000		974,000			-34	%		1,335,000		1,151,000		16	%

Total costs and expenses	$	7,390,000	$	8,710,000			-15	%	$	17,208,000	$	17,388,000		-1	%

	Three months ended June 30, 2026			Three months ended June 30, 2025			% Change			Six months ended June 30, 2026			Six months ended June 30, 2025			% Change

Interest Income	$	2,000		$	13,000			-85	%	$	3,000		$	17,000			-82	%
Interest income on note receivable, related party		6,000		$	12,000			-50	%		12,000			16,000			-25	%
Dividend Income		5,000		$	-			N/A			16,000			-			N/A
Other Income		21,000			4,000			425	%		7,000			10,000			-30	%
Interest Expense		(89,000	)		(123,000	)		-28	%		(128,000	)		(156,000	)		-18	%
Loss on equity method investment		(364,000	)		(2,000	)		18100	%		(367,000	)		(5,000	)		7240	%
Gain (loss) on investments		(830,000	)		1,557,000			-153	%		(1,531,000	)		627,000			-344	%
Impairment of intangible assets		-			(600,000	)		-100	%		-			(600,000	)		-100	%
Loss on sale of real estate		-			(43,000	)		-100	%		-			(727,000	)		-100	%

Total other income (expense)	$	(1,249,000	)	$	818,000					$	(1,988,000	)	$	(818,000	)

Exhibit Number		Exhibit Description

3.1		Certificate of Incorporation *

3.2		Certificate of Incorporation of Document Security Systems, Inc., as amended (incorporated by reference to exhibit 3.1 to Form 8-K dated August 25, 2016).

3.3		Fifth Amended and Restated Bylaws *

10.1		Securities Purchase Agreement between Decentralized Sharing Systems, Inc. and Sharing Services Global Corporation for the sale of HWH Holdings, Inc. (incorporated by reference to exhibit 10.1 to Form 10-Q to the Company’s quarterly report, dated August 13, 2024)

10.2		Securities Purchase Agreement between Decentralized Sharing Systems, Inc. and Sharing Services Global Corporation for the sale of HWH World, Inc. (incorporated by reference to exhibit 10.2 to Form 10-Q to the Company’s quarterly report, dated August 13, 2024)

31.1		Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer. *

31.2		Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer. *

32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002. *

32.2		Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002. *

101.INS		Inline XBRL Instance Document*
101.SCH		Inline XBRL Taxonomy Extension Schema Document*
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document*
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document*
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document*
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document*
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)*

	DSS, INC.

August 14, 2026	By:	/s/ Jason Grady
		Jason Grady
		Interim Chief Executive Officer
		(Principal Executive Officer)

August 14, 2026	By:	/s/ Todd D. Macko
		Todd D. Macko
		Chief Financial Officer
		(Principal Financial and Accounting Officer)

	(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.